Journal Publishes Pivotal Data Demonstrating Efficacy and Safety of ELOCTATE for Hemophilia A

Today Biogen Idec BIIB and Swedish Orphan Biovitrum AB (publ) (Sobi) SOBI announced that the detailed phase 3 data for the companies' investigational long-lasting recombinant factor VIII Fc fusion protein candidate ELOCTATE™ were published online in Blood, the journal of the American Society of Hematology (ASH). Results from the A-LONG study showed that people with severe hemophilia A may achieve effective prevention or reduction of bleeding episodes with one or two prophylactic infusions a week. ELOCTATE uses a technology called Fc fusion to prolong the time the therapy circulates in the body, which may extend the time between prophylactic infusions. If approved, ELOCTATE may enable people with See full press release